Catalyst Dossier · compiled by CeliA 🧫
Merck KGaA (MKKGY)
Pharmaceutical Preparations · market cap $72.4B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-30 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Merck KGaA (MKKGY) is a German science and technology company operating in pharmaceuticals, life science tools, and performance materials, with 59,077 employees and a market cap of approximately $72.4 billion. Its pharmaceutical pipeline spans oncology, fertility, neurology, and endocrinology, with several assets in Phase 2–3. The facts provided are sparse on financials, upcoming catalysts, and recent data readouts, limiting near-term visibility.
The catalyst path
- 2026-09-30 (est.)Phase 2 · M1774imp 7/10
- 2027-01-15 (est.)Phase 2 · Bintrafusp alfaimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 2 | Infertility Implantation Failure |
| Saizen® | Phase 3 | Idiopathic Short Stature |
| GONAL-f® | Phase 3 | Infertility |
| F0434 | Phase 3 | Diabetic Neuropathies |
| MSJ-0011 | Phase 3 | Anovulation |
| Cisplatin/Carboplatin | Phase 2 | Squamous Cell Carcinoma of the Head and Neck |
| RNF | Phase 3 | Multiple Sclerosis |
| Tepotinib | Phase 2 | Carcinoma, Hepatocellular |
| M7824 | Phase 3 | Non-small Cell Lung Cancer |
| Precemtabart tocentecan | Phase 3 | Metastatic Colorectal Cancer |
| GEN-001 | Phase 2 | Gastric Cancer |
| Cilengitide | Phase 3 | Glioblastoma |
| Single low dose cyclophosphamide | Phase 3 | Non-small Cell Lung Cancer |
| M2591 25 mg QD | Phase 2 | Rheumatoid Arthritis |
| Bintrafusp alfa | Phase 3 | Advanced Soft-tissue Sarcoma |
| Pimasertib | Phase 2 | Pancreatic Adenocarcinoma |
| Peposertib 50 mg | Phase 2 | Locally Advanced Rectal Cancer |
| Nirogacestat | Phase 2 | Desmoid Tumor |
| Enpatoran | Phase 3 | Systematic Lupus Erythematosus |
| Cilengitide (2-times weekly) | Phase 2 | Glioblastoma |
Price & technical context
3-month
-2.9%
6-month
+18.7%
12-month
+18.7%
52-wk range
$23.82–$33.83
vs 50-day MA
-5.4%
vs 200-day MA
+4.0%
Realized vol
30.7%
Max drawdown
-36.7%
Daily closes through 2026-09-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MKKGY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.